Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Is Chronic Respiratory Failure in Neuromuscular Diseases Worth Treating
JNNP 61:1-3, Shneerson,J.M., 1996
Multidisciplinary End-of-Life Care for a Patient with Amyotrophic Lateral Sclerosis Requesting Euthanasia
Lancet 402:484, Kruithof,W.J.,et al, 2023
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Long-Term Cognitive Function, Neuroimaging and Quality of Life in Primary CNS Lymphoma
Neurol 81:84-92, Doolittle, N.,et al, 2013
Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review)
Neurol 73:1218-1226, Miller,R.G.,et al, 2009
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy
Arch Neurol 62:128-132, Beenakker,E.A.C.,et al, 2005
Health-Related Quality of Life in Neurology
Arch Neurol 57:1224-1227, Meyers,A.R. et al, 2000
Practice Parameter:The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review), Report of the Quality Standards Subcommittee of the AAN
Neurol 52:1311-1323, Miller,R.G.,et al, 1999
A Prospecitve Study of Preferences and Actual Treatment Choices in ALS
Neurol 53:278-283,248, Albert,S.M.,et al, 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Quality of Life Among Persons with Multiple Sclerosis and Their Caregivers
Neurol 48:74-80, Aronson,K.J., 1997
Doctors & Pts Don't Agree:Cross Sectional Study of Pts' & Doctors'Perceptions & Assessments of Disability in MS
BMJ 314:1580-1583, Rothwell,P.M.,et al, 1997
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Impact of Aerobic Training on Fitness and Quality of Life in Multiple Sclerosis
Ann Neurol 39:432-441, 4221996., Petajan,J.H.,et al, 1996
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Quality of Life in Multiple Sclerosis, Comparison with Inflam Bowel Dis & Rheumatic Arthritis
Arch Neurol 49:1237-1242, Rudick,R.A.,et al, 1992
Cognitive Dysfunction in MS, II. Impact on Employment and Social Functioning
Neurol 41:692-696, Rao,S.M.,et al, 1991